Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) on March 14, 2012. The registrant is a Delaware corporation headquartered in Eden Prairie, Minnesota. The report serves as a Regulation FD disclosure regarding a regulatory milestone for the company's C-Pulse Heart Assist System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific regulatory event and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the completion of the U.S. Food and Drug Administration's (FDA) review of the company's Investigation Device Exemption (IDE) for the C-Pulse Heart Assist System feasibility trial. The FDA notified the company that it has met the requirements of FDA regulation 21CFR 812.150(b)(5) and that no other information is required at this time.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful regulatory clearance to proceed with the feasibility trial as outlined in the IDE.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory process. The document includes a standard disclaimer that the information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the registrant name is Sunshine Heart, Inc., not Nuwellis, Inc.
- Confirm the specific FDA regulation (21CFR 812.150(b)(5)) cited in the clearance.
- Review the attached press release (Exhibit 99.1) for details on the feasibility trial timeline and scope.
- Check subsequent filings for the actual commencement date of the C-Pulse Heart Assist System trial.